Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Boazak M, Kahn B, Cox L, Ragazino J, Goldsmith DR, Cotes RO.

Clin Schizophr Relat Psychoses. 2018 Jun 26. doi: 10.3371/CSRP.BOKA.061518. [Epub ahead of print]

PMID:
29944418
2.

[Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].

Simon L, Cazard F.

Encephale. 2016 Aug;42(4):346-53. doi: 10.1016/j.encep.2016.03.005. Epub 2016 Apr 21. Review. French.

PMID:
27109327
3.

Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.

Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, Shergill S, MacCabe JH.

J Clin Psychiatry. 2015 Nov;76(11):e1410-6. doi: 10.4088/JCP.14m09326.

PMID:
26646037
4.

Hematological adverse events in clozapine-treated children and adolescents.

Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, Nusser L, Kranzler H, Napolitano B, Frederickson A, Henderson I, Rhinewine J, Kumra S.

J Am Acad Child Adolesc Psychiatry. 2005 Oct;44(10):1024-31.

PMID:
16175107
5.

[Clozapine rechallenge in resistant schizophrenia disorder affecting "super sensitive" patients, after neutropenia under clozapine: a case report].

Huguet G, Lillo-Le Louet A, Darnige L, Loo H, Krebs MO.

Encephale. 2013 May;39 Suppl 1:S42-8. doi: 10.1016/j.encep.2013.02.003. Epub 2013 Apr 1. French.

PMID:
23557674
6.

The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review.

Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, Flanagan RJ, Mijovic A, MacCabe JH.

J Clin Psychopharmacol. 2017 Oct;37(5):600-604. doi: 10.1097/JCP.0000000000000767. Review.

PMID:
28817489
7.

Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases.

Manu P, Lapitskaya Y, Shaikh A, Nielsen J.

Am J Ther. 2018 Mar/Apr;25(2):e218-e223. doi: 10.1097/MJT.0000000000000715. Review.

PMID:
29505490
8.

When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Manu P, Sarpal D, Muir O, Kane JM, Correll CU.

Schizophr Res. 2012 Feb;134(2-3):180-6. doi: 10.1016/j.schres.2011.10.014. Epub 2011 Nov 22. Review.

9.

Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Whiskey E, Taylor D.

CNS Drugs. 2007;21(1):25-35. Review.

PMID:
17190527
10.

Lithium and clozapine rechallenge: a retrospective case analysis.

Kanaan RA, Kerwin RW.

J Clin Psychiatry. 2006 May;67(5):756-60.

PMID:
16841625
11.

Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review.

Noël MC, Powell V, Burton L, Panda R, Remington G.

J Clin Psychopharmacol. 2019 Jul/Aug;39(4):380-385. doi: 10.1097/JCP.0000000000001062.

PMID:
31205188
12.

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.

Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E.

BMC Psychiatry. 2016 Dec 12;16(1):441.

13.

Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report.

Crépeau-Gendron G, L'Heureux S.

Early Interv Psychiatry. 2015 Apr;9(2):151-5. doi: 10.1111/eip.12134. Epub 2014 Apr 1.

PMID:
24690066
14.

Late onset clozapine induced agranulocytosis.

Velayudhan R, Kakkan S.

Indian J Psychol Med. 2014 Oct;36(4):425-7. doi: 10.4103/0253-7176.140738.

15.

Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.

Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R, Greenstein D, Overman GP, Rapoport JL, Gogtay N.

J Child Adolesc Psychopharmacol. 2013 Mar;23(2):110-6. doi: 10.1089/cap.2011.0136.

16.

Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.

Myles N, Myles H, Clark SR, Bird R, Siskind D.

Aust N Z J Psychiatry. 2017 Oct;51(10):980-989. doi: 10.1177/0004867417720516. Epub 2017 Jul 27. Review.

PMID:
28747065
17.

Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results.

Ahn YM, Jeong SH, Jang HS, Koo YJ, Kang UG, Lee KY, Kim YS.

Int Clin Psychopharmacol. 2004 Mar;19(2):97-101.

PMID:
15076018
18.

Clozapine-induced neutropenia in children: management with lithium carbonate.

Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL.

J Child Adolesc Psychopharmacol. 2003 Fall;13(3):401-4.

PMID:
14642024
19.

Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

Richardson CM, Davis EA, Vyas GR, DiPaula BA, McMahon RP, Kelly DL.

J Clin Psychiatry. 2016 Nov;77(11):e1454-e1459. doi: 10.4088/JCP.15m10315.

20.

Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases.

Loebstein R, Diav-Citrin O, Atanackovic G, Olivieri NF, Koren G.

Clin Drug Investig. 1997 Jun;13(6):345-9. doi: 10.2165/00044011-199713060-00007.

PMID:
27519496

Supplemental Content

Support Center